Press Releases

 
Press Releases
  Date Title and Summary View
Feb 26, 2003
PITTSBURGH, Feb 26, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that it has named Joseph C. Maroon, M.D., to its Board of Directors. Dr. Maroon currently serves as Professor, Heindl Scholar in Neuroscience and Vice Chairman of the Department of Neurosurgery, University of Pittsburgh Medical Center ("UPMC"). ...
Feb 21, 2003
PITTSBURGH, Feb 21, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. Tamoxifen Citrate is the generic version of AstraZeneca's Nolvadex®...
Feb 20, 2003
PITTSBURGH, Feb 20, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) today announced that it has reached a final agreement with Bristol-Myers Squibb (BMS), which resolves all disputes between the companies related to buspirone. Under the terms of the agreement, Mylan received $35 million and non-exclusive, paid-up, royalty free,...
Dec 20, 2002
PITTSBURGH--(BUSINESS WIRE)--Dec. 20, 2002--Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. District Court for the District of New Jersey has granted summary judgment in Mylan's favor on the issue of non-infringement of Organon's Remeron® patent No. 5,977,099. Mirtazapine i...
Nov 11, 2002
PITTSBURGH--(BUSINESS WIRE)--Nov. 11, 2002--Mylan Laboratories Inc. (NYSE: MYL) today announced that the Food and Drug Administration has granted the first Abbreviated New Drug Application (ANDA) approval for isotretinoin soft-gelatin capsules. Mylan's branded subsidiary Bertek Pharmaceuticals Inc. will market isotretinoin under...
Oct 29, 2002
Business Editors PITTSBURGH, Oct 29, 2002 (BUSINESS WIRE) -- Financial Highlights - Net revenues increased 12% to $319.5 million - Gross profit increased 2% to $166.7 million - Net earnings increased 6% to $68.2 million - Earnings per diluted share increased 8% to $.54 per share Mylan Laboratories Inc. (NYSE: MYL) announced today financial resu...
Oct 28, 2002
PITTSBURGH, Oct 28, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that at its regularly scheduled meeting, the board of directors declared an annual dividend increase of 25% to $.20 per share. The quarterly dividend will increase to $.05 per share. The dividend is payable on Jan. 15, 2003, to shareholders of re...
Oct 16, 2002
PITTSBURGH, Oct 16, 2002 (BUSINESS WIRE) -- Robert J. Coury, Vice Chairman and CEO of Mylan Laboratories Inc. (NYSE: MYL) today acknowledged that Mylan has filed an Abbreviated New Drug Application (ANDA) seeking U.S. Food and Drug Administration (FDA) approval to sell amlodipine besylate tablets (Norvasc®) ...
Oct 15, 2002
PITTSBURGH, Oct 15, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its second quarter fiscal 2003 financial results before the market opens on Tuesday, October 29, 2002. Mylan management will host a conference call and live Webcast at 10:00 AM EST to discuss the financial results and releva...
Oct 9, 2002
PITTSBURGH, Oct 9, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) today announced that it has named Patrick J. Gallagher as Vice President, Business Development. Mr. Gallagher will focus his attention on identifying company and/or product acquisitions, partnerships, licensing activities and other strategic opportunities. ...
Page: FirstPrevious ...
106
NextLast
= add release to Briefcase